Myriad Genetics (MYGN) Prolaris Test Shows Recurrence Prostate Cancer Risk
Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OPKO Health (OPK) Submits Factor VIIa Phase 2a IND to U.S. FDA
- Valeant Pharma (VRX) Forerunner in Dendreon Takeover; Submits $296M 'Stalking Horse' Bid
- OncoMed Pharma (OMED) Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer Gets FDA Orphan Designations
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!